Incyte Corporation 2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015. The filing also reports unaudited fourth-quarter results. Amounts below are in U.S. dollars; financial figures are generally in millions unless stated otherwise.
Business context
Incyte is a biopharmaceutical company focused primarily on oncology. Its marketed product is JAKAFI (ruxolitinib), approved in the United States for intermediate- or high-risk myelofibrosis and for polycythemia vera in patients inadequately responsive or intolerant to hydroxyurea. Novartis commercializes ruxolitinib outside the United States as JAKAVI. Incyte’s pipeline includes partnered and wholly owned clinical-stage programs, including baricitinib, epacadostat and oncology candidates.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 | Change |
|---|---|---|---|
| Total revenue | $753.8 | $511.5 | +47% |
| JAKAFI product revenue, net | $601.0 | $357.6 | +68% |
| JAKAVI royalty revenue | $74.8 | $49.0 | +53% |
| Contract revenue | $77.9 | $104.9 | -26% |
| Research and development expense | $479.5 | $347.5 | +38% |
| Selling, general and administrative expense | $196.6 | $165.8 | +19% |
| Operating income (loss) | $50.7 | $(4.8) | Improved |
| Net income (loss) | $6.5 | $(48.5) | Improved |
| Operating cash flow | $86.5 | $26.3 | Improved |
Calculated operating margin was approximately 6.7% in 2015; net margin was approximately 0.9%. Product-revenue growth reflected a $187.5 million volume increase and a $55.9 million price increase. Lower contract revenue primarily reflected $65 million in Novartis milestones recognized in 2015 versus $92 million in 2014. Cost of product revenue was $27.0 million, including $24.4 million in royalties payable to Novartis on U.S. JAKAFI sales; the company expected product costs to be in the mid-single digits as a percentage of net product sales after remaining pre-launch inventory was used.
Fourth-quarter 2015 revenue was $243.9 million, including $182.0 million of JAKAFI revenue, $23.6 million of JAKAVI royalties and $38.2 million of contract revenue. Net income was $55.2 million. The filing’s quarterly data show a $39.6 million net loss in Q3; the supplied quarterly summary does not clearly identify the specific drivers of the quarter-to-quarter earnings swing.
At year-end, cash, cash equivalents and marketable securities totaled $707.8 million, versus $600.3 million a year earlier. Current assets were $842.4 million and current liabilities $168.0 million, giving working capital of $674.4 million. Operating cash flow was positive, while investing activities used $105.0 million and financing activities provided $87.6 million. Investing outflows included a $39.8 million Agenus investment and $26.0 million of capital expenditures.
Convertible notes had $749.8 million aggregate principal outstanding: $375.0 million due in 2018 and $374.8 million due in 2020. Their year-end carrying value was $619.9 million, reflecting debt discounts and issuance costs. Reported interest expense was $45.6 million, including $33.8 million of non-cash debt-discount amortization. Management stated available liquidity was adequate for at least the next 12 months.
Material changes and developments
- JAKAFI became the dominant revenue source as U.S. sales expanded; JAKAVI royalties also grew. The 2015 revenue mix remained dependent on JAKAFI, JAKAVI royalties and collaboration income.
- R&D spending rose to $479.5 million, reflecting pipeline advancement and, among other items, $25.0 million paid to Hengrui and $20.2 million recorded as R&D expense in connection with the Agenus arrangement. Incyte also incurred $14.4 million of Agenus development costs.
- Incyte entered a global license and collaboration agreement with Hengrui for an investigational PD-1 antibody outside Greater China, paying $25 million upfront. Hengrui may receive up to $770 million in milestones plus royalties.
- Incyte paid $35 million for approximately 7.76 million Agenus shares; the investment was valued at $35.2 million at year-end after a $4.6 million unrealized loss.
- In August 2015, Incyte agreed to buy its Wilmington headquarters and land for approximately $79.9 million, with closing anticipated in Q1 2016. It had paid $8.0 million in deposits by year-end.
- Common shares outstanding increased to 186.7 million at year-end from 170.9 million, mainly reflecting stock-plan activity and conversions of the 2015 notes. The 2015 notes matured in October 2015 and were largely converted into shares.
Outlook, risks and unusual items
- Pipeline outlook: Lilly submitted an NDA to the FDA and an MAA to the European Medicines Agency for baricitinib in rheumatoid arthritis in January 2016. Incyte reported that all four Phase III rheumatoid arthritis trials met their primary endpoints. Incyte subsequently earned $35 million and $20 million milestones for the U.S. and European submissions, respectively.
- Epacadostat: A Phase III study with pembrolizumab for first-line advanced or metastatic melanoma was expected to begin in the first half of 2016. This was forward-looking at the filing date, not a reported outcome.
- Discontinued studies: Following interim analyses, Incyte announced discontinuation of JANUS 1 and 2 and other company-sponsored ruxolitinib solid-tumor studies, as well as INCB39110 in pancreatic cancer. The filing states the analyses did not show sufficient efficacy to continue. These decisions were disclosed in January and February 2016.
- Commercial and patent exposure: JAKAFI sales depend on continued uptake, reimbursement, pricing, regulatory status and reliable third-party manufacturing. The filing warned generic manufacturers could challenge JAKAFI patents after the four-year Hatch-Waxman period ended in November 2015. Patent protection was described as extending to late 2026, with extensions through late 2027 for ruxolitinib patents, subject to applicable conditions.
- Concentration and supply risks: Four customers accounted for 69% of 2015 net product revenue, with the largest representing 28%. Incyte relies on contract manufacturers and noted that certain JAKAFI raw materials were supplied by China-based companies.
- Financial and development risks: Incyte reported a $1.8 billion accumulated deficit and cautioned that it might incur future losses. Clinical outcomes, approvals, milestone receipts, reimbursement, collaboration performance and access to capital remain uncertain. The company also noted potential limits on use of tax attributes and had not updated its Section 382 analysis through 2015.
- Other unusual items: Incyte recognized a $4.6 million unrealized loss on its Agenus investment. The filing reported no legal proceedings. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether JAKAFI sales growth and reimbursement hold up, and how future price increases affect rebates, chargebacks and net revenue.
- Progress and results for baricitinib, epacadostat and other priority pipeline programs, including the status of the planned melanoma Phase III study.
- Implications of the discontinued solid-tumor studies for the remaining ruxolitinib development strategy and R&D spending.
- JAKAFI patent challenges, generic-entry timing and the durability of U.S. and international royalty streams.
- Debt conversion, dilution and repayment exposure, including the 2018 and 2020 notes, and whether cash generation supports planned investment.
- Completion and funding of the approximately $79.9 million headquarters purchase and the related lease-obligation changes.